• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

NovoCure

Court dismisses class action suits against Novocure

December 7, 2017 By Sarah Faulkner

Novocure

Two class action lawsuits filed against Novocure (NSDQ:NVCR) and some of its directors and executives in January were dismissed after the court established that it lacked personal jurisdiction over any of the defendants. In mid-January, Joseph Donahue, Stephen Rosen and Susan Rosen filed two putative class action suits in a New Hampshire court against Novocure, its […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: NovoCure

Novocure nabs reimbursement for Optune in Japan

December 1, 2017 By Sarah Faulkner

Novocure

Novocure (NSDQ:NVCR) shares were up this morning after the Japanese Ministry of Health, Labour and Welfare agreed to reimburse for Optune as a treatment for newly-diagnosed glioblastoma. The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication. As a treatment for newly-diagnosed glioblastoma, Novocure combines its device with the […]

Filed Under: Drug-Device Combinations, Featured, Neurological, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: NovoCure

ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients

September 25, 2017 By Sarah Faulkner

American Society for Radiation Oncology ASTRO annual meeting

Novocure (NSDQ:NVCR) touted data today from the Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-diagnosed glioblastoma. The analyses were presented at the American Society for Radiation Oncology’s 2017 annual meeting in San Diego. The company’s EF-14 trial showed unprecedented five-year survival results in patients with newly-diagnosed GBM, […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Mayo Clinic, NovoCure, Royal Philips, viewray

Novocure misses sales, earnings estimates in Q2

July 27, 2017 By Sarah Faulkner

Novocure

Shares in Novocure (NSDQ:NVCR) fell today after the oncology company missed expectations on Wall Street with its second quarter results. The St. Helier, N.J.-based company reeled in its losses to -$21.2 million on sales of $38.4 million for the 3 months ended June 30, for bottom-line growth of 48% on sales growth of 114% compared with […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Oncology, Wall Street Beat Tagged With: Celgene, NovoCure

Novocure brings Optune tech to drug trial for glioblastoma

July 24, 2017 By Sarah Faulkner

Novocure

Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma. The trial is the first to assess Optune, the company’s “Tumor Treating Fields” delivery device, in combination with an investigational drug. Celgene and Triphase changed their ongoing […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Celgene, NovoCure

Novocure launches Optune, chemotherapy combo trial for glioblastoma

June 8, 2017 By Sarah Faulkner

Novocure

Novocure (NSDQ:NVCR) said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma. In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure’s consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: NovoCure

Novocure touts quality of life data for Optune, chemo combo

May 8, 2017 By Sarah Faulkner

Novocure

Novocure (NSDQ:NVCR) touted health-related quality of life analyses from a pivotal Phase III trial combining its Optune device with standard temozolomide chemotherapy for patients with newly diagnosed glioblastoma. The data showed that adding Optune to temozolomide did not negatively impact health-related quality of life, except for itchy skin which the company attributed to skin irritation […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: NovoCure

Novocure gains on additional Optune data

April 17, 2017 By Brad Perriello

Novocure

Shares in Novocure (NSDQ:NVCR) are on the rise again after the company today cited additional data from a pivotal trial evaluating its Optune device with temozolomide chemotherapy as a treatment for newly-diagnosed glioblastoma. Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication. The […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Radiosurgery, Wall Street Beat Tagged With: NovoCure

Novocure touts long-term data for Optune, chemo combination therapy for glioblastoma

April 3, 2017 By Sarah Faulkner

Novocure

Shares in Novocure (NSDQ:NVCR) jumped nearly 50% today after the company touted 5-year data today from the Phase III pivotal EF-14 trial evaluating its Optune device with temozolomide chemotherapy as a treatment for newly-diagnosed glioblastoma. Data from 695 patients showed a consistent and maintained improvement in overall survival at 2, 3, 4 and 5 years, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Oncology, Wall Street Beat Tagged With: NovoCure

Novocure enrolls 1st patient in TTFields, chemo treatment lung cancer phase III trial

February 15, 2017 By Fink Densford

Novocure

Novocure (NSDQ:NVCR) said today it enrolled the 1st patient in the phase 3 pivotal Lunar trial of its Tumor Treating Field technology for treating patients with advanced non-small cell lung cancer who have failed platinum-based therapy. The prospective, randomized 512-patient trial from the St. Helier, N.J.-based company aims to test the safety and efficacy of its […]

Filed Under: Clinical Trials, Oncology Tagged With: NovoCure

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS